As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizeable potential payout down the line. | Seattle’s Adaptive ...

New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocyt ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.

Parkinson's disease (PD) is an age-related, progressive, neurodegenerative condition, caused by loss of dopamine-producing neurons.

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Roswell Park scientists show that IL-36γ–armored CAR T cells reprogram neutrophils to trigger powerful immune responses ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...